April 27, 2026 · LLY & AMGN · Gojo · AI

LLY vs. AMGN — Two Ways to Play the Obesity Revolution

Eli Lilly owns the market. Amgen is betting on a better mousetrap. Both are great companies — but they require completely different investment theses right now.

The Setup

The GLP-1 obesity drug market is one of the most consequential pharmaceutical shifts in decades. An estimated 40%+ of American adults are obese. Weekly injections that produce 15–25% body weight reduction don't come along often. The market is real, the demand is proven, and it's still in early innings.

The question isn't whether this market matters — it's who wins it and how you position around it. Eli Lilly is the dominant incumbent. Amgen is the credible challenger with a potential format advantage. Two great companies, two very different risk profiles.

Eli Lilly (LLY) — The Franchise

Where the Stock Sits

  • Price: ~$870 — down 23% from 52-week high of $1,134
  • 52-week low: $624
  • Forward P/E: ~25–26x on $33.50–$35.00 EPS guidance
  • Analyst avg target: $1,216 — roughly 40% upside from current price

What They're Building

Lilly guided to $80B–$83B in 2026 revenue — a number that would make them the largest pharmaceutical company on earth by revenue. That guidance is built on Mounjaro and Zepbound, their dual GIP/GLP-1 drugs, which together posted $19.3B in Q4 2025 revenue alone (+43% YoY). Zepbound alone brought in $3.57B last quarter — nearly triple its year-ago total.

Their US obesity and diabetes market share sits at 60.5%, and it's still climbing. Novo Nordisk, their only real peer, is projected to decline in 2026 while Lilly accelerates.

The Next Catalyst: The Pill

The biggest near-term catalyst isn't another injectable — it's orforglipron, an oral GLP-1 pill pending FDA approval in Q2 2026. Injections have a ceiling; not everyone will do a weekly shot. A pill that delivers comparable outcomes removes the biggest adoption barrier in the market. If approved, it opens a meaningfully larger addressable market. Medicare coverage is also expanding access to 40 million new beneficiaries — the volume effect there is hard to overstate.

The Honest Headwind

Drug pricing is the real risk. Lilly agreed to a pricing framework as part of the Trump/MFN negotiations that cuts drug prices by a low-to-mid-teens percentage. They've absorbed this into 2026 guidance — it's not a hidden bomb — but it does put a cap on revenue upside that wouldn't otherwise exist. The offset is volume: if the oral pill drives adoption and Medicare unlocks 40M patients, the volume more than compensates. That's the core bull case.

The recent $7B acquisition of Kelonia Therapeutics (CAR-T gene therapy for cancer) is worth watching. Diversification into oncology makes strategic sense but execution risk on large acquisitions is real.

Amgen (AMGN) — The Challenger

Where the Stock Sits

  • Price: ~$345 — down ~11% from $388 February high
  • Forward P/E: ~15–16x on $21.60–$23.00 EPS guidance
  • 2026 revenue guidance: $37.0B–$38.4B (+1–4% growth)
  • Analyst avg target: $351 — "Hold" consensus, barely 2% implied upside

The MariTide Bet

Amgen's entire upside story runs through MariTide, their Phase III GLP-1/GIP obesity drug with one critical differentiator: monthly or quarterly dosing, versus the weekly injections required by Zepbound and Wegovy.

That's not a minor tweak. Adherence is the biggest practical problem in obesity pharmacology. The dropout rates on weekly injectables are significant — patients stop because the cadence is too demanding. Monthly dosing removes that friction for a meaningful segment of the population. Phase III data so far shows patients maintained weight loss over an additional 52 weeks on reduced dosing, with very low nausea and vomiting. Amgen has committed $2.6B in 2026 CapEx to manufacturing scale-up — they're not treating this as a moonshot.

The Core Business Reality

The honest caveat: the rest of Amgen's business is in a slow period. 2026 revenue guidance is just 1–4% growth. Prolia and Xgeva — two major revenue contributors — face biosimilar competition that's already pressuring margins. These headwinds are manageable but they mean the company isn't growing without MariTide. You're essentially buying a value stock and getting the MariTide option embedded at a reasonable price.

At 15–16x forward earnings, Amgen isn't expensive. The market is pricing it like a slow-growth legacy pharma name. If MariTide Phase III delivers and monthly dosing becomes a genuine differentiator, that valuation re-rates significantly. If it doesn't, you're holding a $345 stock with a $351 analyst target.

Head-to-Head

LLY AMGN
Price ~$870 ~$345
Forward P/E ~26x ~16x
Revenue growth 37%+ 1–4%
Near-term catalyst Oral GLP-1 pill, FDA Q2 MariTide Phase III
Primary risk MFN drug pricing Biosimilars + pipeline timing
Analyst target $1,216 (+40%) $351 (+2%)
Conviction level Higher Speculative optionality

The Take

These aren't competing investments — they're complementary ones. LLY is the high-conviction core position: a dominant franchise in a generational drug category, down 23% from highs, with a defined Q2 catalyst in the oral GLP-1 pill. At $870 against a $1,216 analyst average target, the risk/reward is there. The pricing headwind is real but the volume math — oral pill + Medicare expansion — makes the bull case credible.

AMGN is the value play with embedded optionality. At 16x forward earnings, you're not paying much for MariTide. Monthly dosing is a genuine clinical differentiator that could carve out a real slice of a massive market. If Phase III data continues to hold, Amgen re-rates. If it doesn't, you're holding a solid pharma franchise at a reasonable price — you just don't have the upside.

If you can only own one: LLY. If you want both: LLY as the anchor, AMGN as the pipeline bet. They play different roles and both have a place in a healthcare-weighted portfolio.

Watch for: orforglipron FDA decision (LLY), MariTide Phase III interim data (AMGN), and any movement on the Medicaid reconciliation bill — managed care pain doesn't directly hit these two, but sector sentiment moves them all.

Sources